Almirall Hermal GmbH secures contract for Pharmaceutical products - Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Tildrakizumab, ATC L04AC17 for the period 01012024 - 31122025

Germany, Jan. 14 -- Germany based Almirall Hermal GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products - Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Tildrakizumab, ATC L04AC17 for the period 01012024 - 31122025. The value of the contract is not disclosed.

Published by HT Digital Content Services with permission from Pivotal Sources....